Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Camrelizumab||Phase I||Actionable||In a Phase I trial, Camrelizumab (SHR-1210) demonstrated safety and preliminary anti-tumor activity in patients with advanced solid tumors, with an objective response rate of 31% (18/58, all partial responses) and disease control rate of 46.5% (J Clin Onc. 2017 35:15_suppl, e15572-e15572; NCT02742935).||detail...|
|PubMed Id||Reference Title||Details|
|Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.||Full reference...|